Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
- Conditions
- Asthma
- Interventions
- Drug: Usual Care Inhaled Glucocorticosteroids
- Registration Number
- NCT00404547
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to investigate the effectiveness of Alvesco® (Ciclesonide) compared with usual asthma care in the primary care setting. Patients with a history of asthma for at least 6 months and who, in the opinion of the physician, meet the clinical requirements for treatment with inhaled steroids (ICS) will be enrolled. They will either receive Alvesco® or usual care.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1121
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Alvesco Ciclesonide Alvesco 320mcg / Alvesco 640mcg Usual Care Usual Care Inhaled Glucocorticosteroids -
- Primary Outcome Measures
Name Time Method Change in Mean of Total Score of Asthma Control Questionnaire (ACQ) At the middle and end of the 12 week treatment period The score of the change from baseline ranges from -6 (=best possible outcome) to 6 (=worst possible outcome).
- Secondary Outcome Measures
Name Time Method Change in Patient Assessment of Asthma Control At baseline and at week 12 Patient assessment of asthma control was assessed at baseline and at week 12 using the question "How would you rate the control of your asthma symptoms?". The change in this assessment was categorized in "Improvement" and "Non-Improvement".
Assessment of Patient Compliance During the Study 12 weeks Assessment of Patient Treatment Satisfaction 12 weeks
Trial Locations
- Locations (1)
"Altana Pharma/Nycomed"
🇨🇦York, Canada